{"id":742172,"date":"2012-11-02T14:00:00","date_gmt":"2012-11-02T14:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-will-initiate-interferon-free-phase-ii-clinical-trials-for-mk-5172-an-investigational-once-daily-oral-treatment-for-chronic-hepatitis-c-virus\/"},"modified":"2023-03-22T00:04:21","modified_gmt":"2023-03-22T04:04:21","slug":"merck-will-initiate-interferon-free-phase-ii-clinical-trials-for-mk-5172-an-investigational-once-daily-oral-treatment-for-chronic-hepatitis-c-virus","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-will-initiate-interferon-free-phase-ii-clinical-trials-for-mk-5172-an-investigational-once-daily-oral-treatment-for-chronic-hepatitis-c-virus\/","title":{"rendered":"Merck Will Initiate Interferon-Free Phase II Clinical Trials for MK-5172, an Investigational, Once-Daily, Oral Treatment for Chronic Hepatitis C Virus"},"content":{"rendered":"<div>\n<p><span style=\"font-size:small\">WHITEHOUSE STATION, N.J.&#8211;Today, Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced plans to initiate two new clinical trials with MK-5172, its investigational, once-daily, oral HCV NS3\/4A protease inhibitor for the treatment of chronic hepatitis C (HCV) infection.\u00a0 The trials are designed to assess the efficacy and safety of MK-5172 in all-oral, interferon-free combination regimens in non-cirrhotic, treatment-na\u00efve patients with chronic HCV genotype 1 infection.\u00a0<\/span><\/p>\n<p><span style=\"font-size:small\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u201cFor more than 30 years, Merck has been leading innovation in viral hepatitis.\u00a0 The science is advancing rapidly, and we recognize that future HCV treatment regimens will not include interferon,&#8221; said Roger Pomerantz, MD, FACP, senior vice president and Global Franchise Head for Infectious Diseases, Merck Research Laboratories. &#8220;The start of these new studies is the next step in our efforts to develop novel therapeutic regimens for the treatment of chronic hepatitis C.\u00a0 We look forward to evaluating the potential role of MK-5172 and our other earlier pipeline candidates for chronic HCV as part of our continuing commitment to improving patient care.\u201d\u00a0<\/span><\/p>\n<p><span style=\"font-size:small\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 The first clinical trial will evaluate a 12-week regimen containing MK-5172, MK-8742, an oral NS5A inhibitor in Phase I development, and ribavirin in non-cirrhotic treatment-na\u00efve patients with HCV genotype 1 infection. The second clinical trial will evaluate 12- and 24-week regimens of MK-5172 in combination with ribavirin in non-cirrhotic treatment-na\u00efve patients with HCV genotype 1 infection with an IL-28 CC genotype.\u00a0 More information is available at <a href=\"http:\/\/clinicaltrials.gov\/\">http:\/\/clinicaltrials.gov<\/a> using identifiers, NCT01717326 and NCT01716156, respectively.<\/span><\/p>\n<p><span style=\"font-size:small\">\u00a0<\/span><\/p>\n<p><span style=\"font-size:small\">About MK-5172<\/span><\/p>\n<p><span style=\"font-size:small\">\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 MK-5172 is an investigational, once-daily, oral HCV NS3\/4A protease inhibitor currently in Phase II development that has demonstrated potent in vitro antiviral activity.\u00a0 Early data on MK-5172 has shown a broad HCV genotypic activity spectrum and in vitro activity against genotype 1a and 1b viral variants that have been associated with resistance to other HCV protease inhibitors, including those in development.\u00a0 Given the clinical experience of MK-5172 to date, including its potentially high barrier to resistance and antiviral activity across HCV genotypes, Merck will evaluate MK-5172 in treatment regimens in a broad spectrum of patients with chronic HCV infection.<\/span><\/p>\n<p><span style=\"font-size:small\">\u00a0<\/span><\/p>\n<p><span style=\"font-size:small\">Merck&#8217;s Global Commitment to Advancing Hepatitis Therapy<\/span><\/p>\n<p><span style=\"font-size:small\">Merck is committed to building on its strong legacy in the field of viral hepatitis by continuing to discover, develop and deliver vaccines and medicines to help prevent and treat viral hepatitis. In hepatitis C, company researchers developed the first approved therapy for chronic HCV in 1991 and the first combination therapy in 1998.\u00a0 In addition to ongoing studies for our marketed and investigational medicines for the treatment of chronic HCV, extensive research efforts are underway to develop additional innovative oral therapies for viral hepatitis treatment.<\/span><\/p>\n<p><span style=\"font-size:small\">\u00a0<\/span><\/p>\n<p><span style=\"font-size:small\">About Merck<\/span><\/p>\n<p><span style=\"font-size:small\">Today&#8217;s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United Statesand Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/\">vip2-msd.com\/merckcom-migrated<\/a> and connect with us on Twitter, Facebook and YouTube.<\/span><\/p>\n<p><span style=\"font-size:small\">\u00a0<\/span><\/p>\n<p><span style=\"font-size:small\">Forward-Looking Statement<\/span><\/p>\n<p><span style=\"font-size:small\">This news release includes \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger<\/span><\/p>\n<p><span style=\"font-size:small\">between Merck and Schering-Plough, including future financial and operating results, the combined company\u2019s plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of<\/span><\/p>\n<\/div>\n<p><span style=\"font-size:small\">Merck\u2019s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.<\/span><\/p>\n<p><span style=\"font-size:small\">The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that all of the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; Merck\u2019s ability to accurately predict future market conditions; dependence on the effectiveness of Merck\u2019s patents and other protections for innovative products; and the exposure to litigation and\/or regulatory actions.<\/span><\/p>\n<p><span style=\"font-size:small\">Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck\u2019s 2011 Annual Report on Form 10-K and the company\u2019s other filings with the Securities and Exchange Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/www.sec.gov\" title=\"www.sec.gov\">www.sec.gov<\/a>).<\/span><\/p>\n<p>Caroline Lappetito<br \/>\n(267) 305-7369\n<\/p>\n<p>Lainie Keller<br \/>\n(908) 423-4187\n<\/p>\n<p>Investor Contacts:\n<\/p>\n<p>Carol Ferguson<br \/>\n(908) 423-4465\n<\/p>\n<p>Justin Holko<br \/>\n(908) 423-5088<\/p>\n","protected":false},"excerpt":{"rendered":"<p>WHITEHOUSE STATION, N.J.-Today, Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced plans to initiate two new clinical trials with MK-5172, its investigational, once-daily, oral HCV NS3\/4A protease inhibitor for the treatment of chronic hepatitis C (HCV) infection.\u00a0 The trials are designed to assess the efficacy and safety of MK-5172 in all-oral, interferon-free combination regimens in non-cirrhotic, treatment-na\u00efve patients with chronic HCV genotype 1 infection. \u201cFor more than 30 years, Merck has been leading innovation in viral hepatitis.\u00a0 The science is advancing rapidly, and we recognize that future HCV treatment regimens will not include interferon,&#8221; said Roger Pomerantz, MD, FACP, senior vice president and Global Franchise Head for Infectious Diseases, Merck Research Laboratories. &#8220;The start of these new studies is the next step in our efforts to develop novel therapeutic regimens for the treatment of chronic hepatitis C.\u00a0 We look forward to<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[289,56],"class_list":["post-742172","news_item","type-news_item","status-publish","hentry","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Will Initiate Interferon-Free Phase II Clinical Trials for MK-5172, an Investigational, Once-Daily, Oral Treatment for Chronic Hepatitis C Virus - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-will-initiate-interferon-free-phase-ii-clinical-trials-for-mk-5172-an-investigational-once-daily-oral-treatment-for-chronic-hepatitis-c-virus\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Will Initiate Interferon-Free Phase II Clinical Trials for MK-5172, an Investigational, Once-Daily, Oral Treatment for Chronic Hepatitis C Virus - Merck.com\" \/>\n<meta property=\"og:description\" content=\"WHITEHOUSE STATION, N.J.-Today, Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced plans to initiate two new clinical trials with MK-5172, its investigational, once-daily, oral HCV NS3\/4A protease inhibitor for the treatment of chronic hepatitis C (HCV) infection.\u00a0 The trials are designed to assess the efficacy and safety of MK-5172 in all-oral, interferon-free combination regimens in non-cirrhotic, treatment-na\u00efve patients with chronic HCV genotype 1 infection. \u201cFor more than 30 years, Merck has been leading innovation in viral hepatitis.\u00a0 The science is advancing rapidly, and we recognize that future HCV treatment regimens will not include interferon,&quot; said Roger Pomerantz, MD, FACP, senior vice president and Global Franchise Head for Infectious Diseases, Merck Research Laboratories. &quot;The start of these new studies is the next step in our efforts to develop novel therapeutic regimens for the treatment of chronic hepatitis C.\u00a0 We look forward to\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-will-initiate-interferon-free-phase-ii-clinical-trials-for-mk-5172-an-investigational-once-daily-oral-treatment-for-chronic-hepatitis-c-virus\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-will-initiate-interferon-free-phase-ii-clinical-trials-for-mk-5172-an-investigational-once-daily-oral-treatment-for-chronic-hepatitis-c-virus\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-will-initiate-interferon-free-phase-ii-clinical-trials-for-mk-5172-an-investigational-once-daily-oral-treatment-for-chronic-hepatitis-c-virus\\\/\",\"name\":\"Merck Will Initiate Interferon-Free Phase II Clinical Trials for MK-5172, an Investigational, Once-Daily, Oral Treatment for Chronic Hepatitis C Virus - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2012-11-02T14:00:00+00:00\",\"dateModified\":\"2023-03-22T04:04:21+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-will-initiate-interferon-free-phase-ii-clinical-trials-for-mk-5172-an-investigational-once-daily-oral-treatment-for-chronic-hepatitis-c-virus\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-will-initiate-interferon-free-phase-ii-clinical-trials-for-mk-5172-an-investigational-once-daily-oral-treatment-for-chronic-hepatitis-c-virus\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-will-initiate-interferon-free-phase-ii-clinical-trials-for-mk-5172-an-investigational-once-daily-oral-treatment-for-chronic-hepatitis-c-virus\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Will Initiate Interferon-Free Phase II Clinical Trials for MK-5172, an Investigational, Once-Daily, Oral Treatment for Chronic Hepatitis C Virus\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Will Initiate Interferon-Free Phase II Clinical Trials for MK-5172, an Investigational, Once-Daily, Oral Treatment for Chronic Hepatitis C Virus - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-will-initiate-interferon-free-phase-ii-clinical-trials-for-mk-5172-an-investigational-once-daily-oral-treatment-for-chronic-hepatitis-c-virus\/","og_locale":"en_US","og_type":"article","og_title":"Merck Will Initiate Interferon-Free Phase II Clinical Trials for MK-5172, an Investigational, Once-Daily, Oral Treatment for Chronic Hepatitis C Virus - Merck.com","og_description":"WHITEHOUSE STATION, N.J.-Today, Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced plans to initiate two new clinical trials with MK-5172, its investigational, once-daily, oral HCV NS3\/4A protease inhibitor for the treatment of chronic hepatitis C (HCV) infection.\u00a0 The trials are designed to assess the efficacy and safety of MK-5172 in all-oral, interferon-free combination regimens in non-cirrhotic, treatment-na\u00efve patients with chronic HCV genotype 1 infection. \u201cFor more than 30 years, Merck has been leading innovation in viral hepatitis.\u00a0 The science is advancing rapidly, and we recognize that future HCV treatment regimens will not include interferon,\" said Roger Pomerantz, MD, FACP, senior vice president and Global Franchise Head for Infectious Diseases, Merck Research Laboratories. \"The start of these new studies is the next step in our efforts to develop novel therapeutic regimens for the treatment of chronic hepatitis C.\u00a0 We look forward to","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-will-initiate-interferon-free-phase-ii-clinical-trials-for-mk-5172-an-investigational-once-daily-oral-treatment-for-chronic-hepatitis-c-virus\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:21+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-will-initiate-interferon-free-phase-ii-clinical-trials-for-mk-5172-an-investigational-once-daily-oral-treatment-for-chronic-hepatitis-c-virus\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-will-initiate-interferon-free-phase-ii-clinical-trials-for-mk-5172-an-investigational-once-daily-oral-treatment-for-chronic-hepatitis-c-virus\/","name":"Merck Will Initiate Interferon-Free Phase II Clinical Trials for MK-5172, an Investigational, Once-Daily, Oral Treatment for Chronic Hepatitis C Virus - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2012-11-02T14:00:00+00:00","dateModified":"2023-03-22T04:04:21+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-will-initiate-interferon-free-phase-ii-clinical-trials-for-mk-5172-an-investigational-once-daily-oral-treatment-for-chronic-hepatitis-c-virus\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-will-initiate-interferon-free-phase-ii-clinical-trials-for-mk-5172-an-investigational-once-daily-oral-treatment-for-chronic-hepatitis-c-virus\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-will-initiate-interferon-free-phase-ii-clinical-trials-for-mk-5172-an-investigational-once-daily-oral-treatment-for-chronic-hepatitis-c-virus\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Will Initiate Interferon-Free Phase II Clinical Trials for MK-5172, an Investigational, Once-Daily, Oral Treatment for Chronic Hepatitis C Virus"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"8f54be4f-a47c-4ada-8b2e-68f07f943f27","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742172","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742172\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742172"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742172"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}